See more : Viscofan, S.A. (VIS.MC) Income Statement Analysis – Financial Results
Complete financial analysis of Guangdong Taiantang Pharmaceutical Co., Ltd. (002433.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guangdong Taiantang Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Zinzino AB (publ) (ZNZNF) Income Statement Analysis – Financial Results
- Hoku Corporation (HOKUQ) Income Statement Analysis – Financial Results
- Great Panther Mining Limited (GPL) Income Statement Analysis – Financial Results
- Strong Petrochemical Holdings Limited (0852.HK) Income Statement Analysis – Financial Results
- Kesselrun Resources Ltd. (0V2Y.L) Income Statement Analysis – Financial Results
Guangdong Taiantang Pharmaceutical Co., Ltd. (002433.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.tatonline.net
About Guangdong Taiantang Pharmaceutical Co., Ltd.
Guangdong Taiantang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese patent medicines in China. It offers medicines in the forms of creams, ointments, tablets, capsules, pills, and solutions for the areas, including reproductive health, skin health, cardiovascular, cerebrovascular, dermatology, anti-inflammatory, and other areas, as well as acquires, cultivates, processes, and sells Chinese medicinal materials. The company was founded in 1995 and is headquartered in Shantou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 410.36M | 724.84M | 2.26B | 3.58B | 4.01B | 3.32B | 3.24B | 3.08B | 2.37B | 1.23B | 785.17M | 517.88M | 417.37M | 314.04M | 288.33M | 243.78M | 182.97M |
| Cost of Revenue | 341.20M | 442.46M | 1.73B | 2.65B | 3.03B | 2.39B | 2.27B | 2.25B | 1.70B | 768.35M | 460.66M | 279.49M | 240.31M | 189.30M | 176.32M | 149.57M | 113.83M |
| Gross Profit | 69.17M | 282.38M | 529.21M | 931.66M | 979.75M | 920.65M | 969.28M | 830.32M | 674.53M | 459.28M | 324.51M | 238.39M | 177.05M | 124.74M | 112.01M | 94.20M | 69.15M |
| Gross Profit Ratio | 16.85% | 38.96% | 23.37% | 26.01% | 24.41% | 27.77% | 29.93% | 27.00% | 28.44% | 37.41% | 41.33% | 46.03% | 42.42% | 39.72% | 38.85% | 38.64% | 37.79% |
| Research & Development | 7.47M | 26.72M | 30.40M | 20.38M | 24.26M | 22.91M | 30.00M | 20.44M | 21.62M | 7.22M | 2.96M | 771.41K | 438.49K | 208.28K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 36.65M | 34.37M | 37.22M | 49.85M | 45.30M | 39.91M | 33.72M | 37.71M | 30.37M | 16.10M | 12.17M | 13.44M | 10.32M | 7.44M | 11.92M | 14.10M | 13.10M |
| Selling & Marketing | 217.56M | 117.70M | 369.19M | 549.27M | 511.02M | 446.20M | 350.70M | 334.46M | 295.90M | 131.12M | 93.24M | 51.05M | 59.94M | 40.46M | 28.96M | 29.66M | 18.09M |
| SG&A | 254.21M | 152.07M | 406.42M | 599.13M | 556.32M | 486.11M | 384.42M | 372.18M | 326.26M | 147.22M | 105.41M | 64.49M | 70.26M | 47.90M | 40.88M | 43.75M | 31.19M |
| Other Expenses | -71.58M | 140.32M | 180.19M | 165.22M | 152.00M | -880.73K | 49.87M | 29.28M | 3.17M | 4.25M | 3.50M | 9.88M | 1.34M | 2.72M | 5.99M | 714.83K | 390.01K |
| Operating Expenses | 427.69M | 319.10M | 617.00M | 784.73M | 732.58M | 666.83M | 553.30M | 501.74M | 443.98M | 222.62M | 155.01M | 106.25M | 91.89M | 60.29M | 42.92M | 45.49M | 32.51M |
| Cost & Expenses | 768.89M | 761.57M | 2.35B | 3.44B | 3.77B | 3.06B | 2.82B | 2.75B | 2.14B | 990.97M | 615.67M | 385.74M | 332.20M | 249.59M | 219.24M | 195.06M | 146.34M |
| Interest Income | 17.35M | 108.47K | 551.99K | 1.48M | 2.09M | 1.16M | 2.27M | 4.43M | 8.04M | 4.08M | 4.93M | 1.51M | 5.06M | 3.46M | 18.84K | 0.00 | 0.00 |
| Interest Expense | 195.86M | 105.28M | 153.27M | 137.61M | 139.35M | 129.29M | 92.33M | 59.15M | 12.90M | 21.94M | 14.59M | 21.12M | 3.47M | 2.72M | 3.53M | 2.33M | 944.68K |
| Depreciation & Amortization | 106.82M | 127.75M | 87.53M | 106.13M | 95.62M | 83.86M | 76.01M | 54.10M | 50.88M | 47.85M | 37.48M | 25.65M | 14.06M | 7.12M | 4.62M | 4.01M | 6.71M |
| EBITDA | -312.93M | 58.86M | -260.90K | 291.08M | 374.04M | 603.52M | 542.32M | 414.81M | 291.84M | 297.16M | 214.85M | 168.14M | 106.82M | 78.28M | 75.90M | 52.64M | 43.85M |
| EBITDA Ratio | -76.26% | 8.12% | -0.01% | 8.13% | 9.32% | 18.20% | 16.74% | 13.49% | 12.31% | 24.21% | 27.36% | 32.47% | 25.59% | 24.93% | 26.32% | 21.59% | 23.96% |
| Operating Income | -2.21B | -68.89M | -87.80M | 184.95M | 278.41M | 329.47M | 304.33M | 266.12M | 219.12M | 203.54M | 153.05M | 102.67M | 84.81M | 63.64M | 64.71M | 46.46M | 35.19M |
| Operating Income Ratio | -539.49% | -9.50% | -3.88% | 5.16% | 6.94% | 9.94% | 9.40% | 8.65% | 9.24% | 16.58% | 19.49% | 19.82% | 20.32% | 20.27% | 22.44% | 19.06% | 19.23% |
| Total Other Income/Expenses | -1.91B | -751.43M | -745.36M | -93.60M | -154.30M | -880.73K | -42.01M | -27.27M | -2.68M | -16.41M | -6.78M | -11.36M | 2.73M | 3.36M | 2.32M | 714.83K | 390.01K |
| Income Before Tax | -2.29B | -820.32M | -842.23M | 38.04M | 124.11M | 328.59M | 354.20M | 295.15M | 222.11M | 207.79M | 156.48M | 111.95M | 87.54M | 67.00M | 67.03M | 47.18M | 35.58M |
| Income Before Tax Ratio | -556.93% | -113.17% | -37.20% | 1.06% | 3.09% | 9.91% | 10.94% | 9.60% | 9.37% | 16.93% | 19.93% | 21.62% | 20.98% | 21.34% | 23.25% | 19.35% | 19.45% |
| Income Tax Expense | 9.32M | 33.26M | -10.30M | 11.16M | 22.29M | 53.41M | 59.89M | 42.27M | 26.53M | 15.41M | 19.19M | 21.47M | 13.39M | 10.55M | 13.18M | 7.67M | 5.22M |
| Net Income | -2.21B | -853.58M | -831.92M | 22.23M | 96.09M | 270.89M | 290.40M | 243.33M | 190.12M | 186.31M | 132.90M | 88.05M | 74.15M | 56.45M | 53.89M | 38.29M | 30.71M |
| Net Income Ratio | -538.57% | -117.76% | -36.74% | 0.62% | 2.39% | 8.17% | 8.97% | 7.91% | 8.02% | 15.18% | 16.93% | 17.00% | 17.77% | 17.98% | 18.69% | 15.71% | 16.78% |
| EPS | -2.88 | -1.11 | -1.08 | 0.03 | 0.13 | 0.35 | 0.38 | 0.32 | 0.26 | 0.30 | 0.24 | 0.22 | 0.19 | 0.16 | 0.18 | 0.13 | 0.12 |
| EPS Diluted | -2.88 | -1.11 | -1.08 | 0.03 | 0.13 | 0.35 | 0.32 | 0.31 | 0.26 | 0.30 | 0.24 | 0.22 | 0.19 | 0.16 | 0.18 | 0.13 | 0.12 |
| Weighted Avg Shares Out | 767.39M | 766.77M | 766.77M | 766.77M | 766.77M | 766.77M | 764.21M | 760.40M | 731.24M | 621.02M | 553.74M | 400.24M | 400.82M | 347.38M | 299.39M | 300.28M | 250.65M |
| Weighted Avg Shares Out (Dil) | 767.39M | 766.77M | 766.77M | 766.77M | 766.77M | 773.98M | 907.50M | 784.93M | 731.24M | 621.02M | 553.74M | 400.24M | 400.82M | 347.38M | 299.39M | 300.28M | 250.65M |
Source: https://incomestatements.info
Category: Stock Reports